High dose imatinib (STI571, Gleevec®) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC):: Follow-up of the phase II studies.

被引：0
|
作者：
Talpaz, M
Goldman, JM
Sawyers, CL
Hochhaus, A
Silver, RT
Smith, BD
So, C
Gathmann, I
Druker, BJ
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3369
引用
收藏
页码：905A / 906A
页数：2
相关论文
共 50 条
  • [21] Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or chronic phase (CP): Preliminary safety analysis
    Nicolini, Franck
    Alimena, Giuliana
    Al-Ali, Haifa-Kathrin
    Zaritskey, Andrey
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    Hsu, Yanzhi
    Veronese, Maria Luisa
    Rizzieri, David A.
    BLOOD, 2007, 110 (11) : 870A - 870A
  • [22] IMATINIB 600 MG IN ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA INDUCES DURABLE CYTOGENETIC RESPONSES IN THE LONG-TERM: THE GIMEMA CML WORKING PARTY EXPERIENCE AFTER A 7-YEAR FOLLOW-UP
    Palandri, F.
    Castagnetti, F.
    Testoni, N.
    Alimena, G.
    Breccia, M.
    Levato, F.
    Specchia, G.
    Martino, B.
    Rege-Cambrin, G.
    Miglino, M.
    Saglio, G.
    Pane, F.
    Martinelli, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2008, 93 : S64 - S64
  • [23] Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Resta, D
    Capdeville, R
    Druker, B
    BLOOD, 2000, 96 (11) : 470A - 470A
  • [24] IMATINIB 600 MG ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA INDUCES DURABLE CYTOGENETIC RESPONSES IN THE LONG-TERM: THE GIMEMA CML WORKING PARTY EXPERIENCE AFTER A 7-YEAR FOLLOW-UP
    Palandri, F.
    Castagnetti, F.
    Testoni, N.
    Alimena, G.
    Rege-Cambrin, G.
    Breccia, M.
    Specchia, G.
    Bruno, B.
    Miglino, M.
    Levato, F.
    Saglio, G.
    Pane, F.
    Martinelli, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 49 - 50
  • [25] Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up
    Spector, Nelson
    Leber, Brian
    Lipton, Jeffrey Howard
    De Souza, Carmino
    Moiraghi, Beatriz
    Steegmann, Juan Luis
    Schwarer, Anthony P.
    Cervantes, Francisco
    Hughes, Timothy P.
    Purkayastha, Das
    Collins, LaTonya R.
    Szczudlo, Tomasz K.
    Rea, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Pharmacokinetic analysis of nilotinib in Chinese chronic myelogenous leukemia (CML) patients (pts) with imatinib-resistant or-intolerant disease in blast crisis (BC), accelerated phase (AP) or chronic phase (CP)
    Zhou, L.
    Hu, P.
    Meng, F.
    Wang, J.
    Wang, C.
    Hu, Z.
    Shen, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
    Shah, Neil P.
    Guilhot, Francois
    Cortes, Jorge E.
    Schiffer, Charles A.
    le Coutre, Philipp
    Bruemmendorf, Tim H.
    Kantarjian, Hagop M.
    Hochhaus, Andreas
    Rousselot, Philippe
    Mohamed, Hesham
    Healey, Diane
    Cunningham, Michael
    Saglio, Giuseppe
    BLOOD, 2014, 123 (15) : 2317 - 2324
  • [28] Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib
    Giles, F. J.
    Kantarjian, H.
    le Coutre, P. D.
    Baccarani, M.
    Blakesley, R. E.
    Gallagher, N. J.
    Gillis, K.
    Larson, R. A.
    Ottmann, O. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] NILOTINIB INDUCES RAPID AND DURABLE RESPONSES WITH 24-MONTH MINIMUM FOLLOW-UP IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN BLAST CRISIS (CML-BC)
    Giles, F.
    Kantarjian, H.
    le Coutre, P.
    Baccarani, M.
    Blakesley, R.
    Gallagher, N.
    Gillis, K.
    Larson, R.
    Ottmann, O.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 469 - 469
  • [30] Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
    Larson, Richard A.
    Kim, Dong-Wook
    Issaragrilsil, Surapol
    le Coutre, Philipp
    Dorlhiac Llacer, Pedro Enrique
    Etienne, Gabriel
    Clark, Richard E.
    Flinn, Ian
    Nakamae, Hirohisa
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kantarjian, Hagop M.
    Donohue, Breanne
    Deng, Weiping
    Menssen, Hans D.
    Hughes, Timothy P.
    BLOOD, 2014, 124 (21)
12345